^18F-FDGPET/CT在非霍奇金淋巴瘤疗效评价中的应用价值

目的探讨18F-FDGPET/CT显像对非霍奇金淋巴瘤治疗疗效的价值。方法收集2004.9～2008.11在我院PET中心接受至少2次PET/CT检查,分为初诊的在PET/CT扫描前未治疗非霍奇金淋巴瘤组（A组）或经过放疗及化疗后的治疗组（B组）为研究对象。所有病例随访至少6个月。结果未治疗的非霍奇金淋巴瘤组的32例中,3例颅内淋巴瘤中2例在9个月内复发;21例经过6个疗程化疗后PET/CT为阴性,仅有1例复发（5%）;1例3个疗程化疗后SUV降低达92.9%的化疗效果佳;而8例PET/CT阳性者预后不理想。治疗组病例中,PET/CT阴性的11例NHL,复发3例（27%）;而PET/CT阳性的25例中,19例复发（76%）,PET阳性组的肿瘤复发与阴性组差异有显著性（P〈0.05）。结论本研究表明18F-FDGPET/CT显像能很好的评价非霍奇金淋巴瘤的治疗效果,且可早期预测治疗效果及预后。

18F-FDG PET/CT evaluation of response to treatment in non-Hodgkin lymphoma

Objective To evaluate the usefulness of 18F-FDG PET/CT imaging in monitoring the response to treatment of non-Hodgkin lymphoma（NHL）.Methods From September 2004 to November 2008,patients performed at least twice PET/CT exams in our center who were diagnosed as NHL or after radiotherapy and chemotherapy.Sixty-eight cases were divided into 2 groups.Group A with 32 cases who had not performed chemotherapy or radiotherapy before PET/CT scans,and Group B with 36 cases who had got various cycles of chemotherapy or radiotherapy.All cases were followed up at least 6 months.Results Among group A,the 32 cases had performed 78 PET/CT scans,2 of 3 cases with primary central nerves lymphoma had relapsed less than 9 months.There was only one case who had relapsed with negative PET/CT scan with 6 cycles of chemotherapy in 21 cases.Eight cases had positive lesions after therapy.In group B,the 36 cases had performed 109 PET/CT scans,11 cases of post-therapy were negative with PET/CT scans,only 3 cases were relapsed（27%）,however the 25 cases with positive PET/CT were received more therapy,19 cases were relapsed（76%）.Statistically significant difference in tumor relapse was found between positive and negative PET results.Conclusions This study indicated that 18F-FDG PET/CT imaging can evaluate the response of treatment in NHL.Patients who showed negative PET/CT results had better prognosis compared to those with positive results.